atai Life Sciences B.V. is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai Life Sciences B.V. is based in BERLIN.
| Revenue (Most Recent Fiscal Year) | $0.31M |
| Net Income (Most Recent Fiscal Year) | $-149.27M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 6.47 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -5180.12% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -85.43% |
| Return on Assets (Trailing 12 Months) | -64.38% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.02 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.02 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.02 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.67 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.14 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.93 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.69 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 214.34M |
| Free Float | 156.90M |
| Market Capitalization | $996.67M |
| Average Volume (Last 20 Days) | 6.00M |
| Beta (Past 60 Months) | 1.54 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 26.80% |
| Percentage Held By Institutions (Latest 13F Reports) | 28.41% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |